{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:34:55Z","timestamp":1759412095273},"reference-count":24,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.08.047","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T14:46:45Z","timestamp":1504622805000},"page":"5618-5621","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System"],"prefix":"10.1016","volume":"35","author":[{"given":"Emily Jane","family":"Woo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Jankosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.08.047_b0005","unstructured":"Flublok approval letter. <http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm410628.htm> [accessed 3\/1\/17]."},{"key":"10.1016\/j.vaccine.2017.08.047_b0010","doi-asserted-by":"crossref","unstructured":"CDC. Recommendations and Reports. Prevention and control of seasonal influenza with vaccines recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2016-17 influenza season. MMWR Recomm Rep 2016;65(2).","DOI":"10.15585\/mmwr.rr6505a1"},{"key":"10.1016\/j.vaccine.2017.08.047_b0015","unstructured":"Flublok package insert. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM336020.pdf> [accessed 3\/1\/17]."},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.047_b0020","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"10.1016\/j.vaccine.2017.08.047_b0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2017.08.047_b0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3928\/0090-4481-20040901-11","article-title":"The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety","volume":"33","author":"Iskander","year":"2004","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.vaccine.2017.08.047_b0035","unstructured":"Code of Federal Regulations. 21 15 600.80."},{"issue":"31","key":"10.1016\/j.vaccine.2017.08.047_b0040","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.047_b0045","doi-asserted-by":"crossref","unstructured":"DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. In: Proceeding of the conference on knowledge discovery and data; 2001 Aug 26\u201329. San Diego (CA): ACM Press. p. 67\u201376.","DOI":"10.1145\/502512.502526"},{"key":"10.1016\/j.vaccine.2017.08.047_b0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s Spontaneous Reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Safety"},{"issue":"22","key":"10.1016\/j.vaccine.2017.08.047_b0055","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.vaccine.2016.03.048","article-title":"Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2017.08.047_b0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/cid\/ciu948","article-title":"Allergic reactions after egg-free recombinant influenza vaccine: reports to the US vaccine adverse event reporting system","volume":"60","author":"Woo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.047_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.07.046","article-title":"Public health agency of canada\/canadian institutes of health research influenza research network. Egg-allergic patients can be safely vaccinated against influenza","volume":"130","author":"Des Roches","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.08.047_b0070","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaip.2014.08.008","article-title":"Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine","volume":"3","author":"Des Roches","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2017.08.047_b0075","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaci.2014.12.1925","article-title":"Safety of live attenuated influenza vaccine in atopic children with egg allergy","volume":"136","author":"Turner","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.08.047_b0080","doi-asserted-by":"crossref","first-page":"h6291","DOI":"10.1136\/bmj.h6291","article-title":"Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study","volume":"351","author":"Turner","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.08.047_b0085","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaip.2014.11.017","article-title":"Intranasal live-attenuated influenza vaccine (LAIV) is unlikely to cause egg-mediated allergic reactions in egg-allergic children","volume":"3","author":"Turner","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.vaccine.2017.08.047_b0090","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.anai.2012.09.011","article-title":"Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy","volume":"109","author":"Greenhawt","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2017.08.047_b0095","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1542\/peds.2009-2512","article-title":"Safety of influenza vaccine administration in egg-allergic patients","volume":"125","author":"Chung","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.08.047_b0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.anai.2011.01.024","article-title":"Safe administration of seasonal influenza vaccine to children with egg allergy of all severities","volume":"106","author":"Howe","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2017.08.047_b0105","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaci.2011.02.013","article-title":"Single-dose influenza vaccine to patients with egg allergy in a multicenter study","volume":"128","author":"Webb","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2017.08.047_b0110","unstructured":"Grohskopf LA, Shay DK, Shimabukuro TT, Leslie Z, Sokolow MS, Wendy AK, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), United States. MMWR 2013; 62(RR07). p. 1\u201343."},{"issue":"6","key":"10.1016\/j.vaccine.2017.08.047_b0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in US infants","volume":"370","author":"Yih","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.08.047_b0120","unstructured":"Flublok Quadrivalent approval letter. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM524732.pdf> [accessed 3\/1\/17]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T04:35:50Z","timestamp":1570077350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17311350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":24,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17311350"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}